作者
Kathleen K Christians, Susan Tsai, Anna Mahmoud, Paul Ritch, James P Thomas, Lauren Wiebe, Tracy Kelly, Beth Erickson, Huamin Wang, Douglas B Evans, Ben George
发表日期
2014/3/1
期刊
The oncologist
卷号
19
期号
3
页码范围
266-274
出版商
Oxford University Press
简介
Abstract
Background
Borderline resectable pancreatic cancer is best treated by multimodality therapy. FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) tripled the response rate and significantly increased median survival for patients with advanced pancreatic cancer and shows promise for neoadjuvant use. Toxicity concerns prompted a careful analysis of our initial FOLFIRINOX experience.
Methods
All patients diagnosed with borderline resectable, biopsy-proven pancreatic adenocarcinoma treated with neoadjuvant FOLFIRINOX between July 2010 and December 2012 were reviewed. Primary outcome was surgical resectability. Secondary outcomes were treatment-related toxicities and survival.
Results
FOLFIRINOX followed by gemcitabine- or capecitabine-based chemoradiation was initiated in 18 patients. The most common grade 3 …
学术搜索中的文章
KK Christians, S Tsai, A Mahmoud, P Ritch, JP Thomas… - The oncologist, 2014